drugset / Trial / NCT00050388

Phase II Trial of Allovectin-7® for Head and Neck Cancer

NCT00050388

Phase 3 Completed Vical
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink head and neck tumors. The trial will also examine if treatment can boost the immune system and if this treatment can improve the time to disease progression.

Timeline

Start
Primary completion
Completion
2002-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Allovectin-7® Other / unclassified Other